机体最大耐受剂量(MTD)下的顺铂与卡铂治疗晚期肺癌临床效果的对照分析  

Comparison of Effect of I. V. Cisplatin (DDP) with I. V. Carboplatin(CDP) in the Treatment of Advanced Lung Cancer under Maximum Tolerance Dosages (MTD)

作　　者：华新民[1] 邓平[1] 刘克[1] 段贵新[1] 张玉清[1] 卢伟平[1] 韦文赞 单征[1] 

机构地区：[1]吉林省肿瘤医院胸科,长春市130012

出　　处：《中国肿瘤临床》1994年第8期621-624,共4页Chinese Journal of Clinical Oncology

摘　　要：以顺铂100~120mg/m^2、卡铂400~450mg/m^2分别联合(1)ADM60~80mg、Vp_(16)100mg×5日(各10例),(2)VP_(16)200mg×5日(各3例),(3)在(1)的基础上加美蓝400mg×3日(各1例)治疗病理类型、临床分期相同的晚期肺癌各14例.其缓解率在顺铂组及卡铂组分别为78.5%及57.1%.两组均有1/3病例出现了不同形式的重度毒副反应.本研究表明以机体最大耐受剂量(MTO)联合以相同的药物治疗晚期肺癌,特别是非小细胞肺癌顺铂较卡铂效果好.A comparison of effects of DDP 100-120mg/m2 and CDP 400-450mg/m2 was put in trial.The combination protocols used were the same.i. e. (l)ADM 60-80mg(10 cases),VP-16 100mg × 5(100 cases),(2)VP-16 200mg×5 (3 cases),(3)in addition to(l)was added Methylene Blue 400mg×3(l cases). 14 patients with late lung cancer with similar histologic type and clinical stage were treated. The overall remission rates in DDP and CDP group were78. 5%and57. 1% respectively. Severe drug toxicities were observed in 1/3 of the patients. It is shown that DDP was superior to CDP under MTD regimen,especially for NSCLC patients.

关 键 词：顺铂 卡铂 剂量 癌 肺肿瘤 

分 类 号：R734.205[医药卫生—肿瘤]